| scholarly article | Q13442814 |
| P2093 | author name string | Nigel Irwin | |
| Peter R Flatt | |||
| P2860 | cites work | Effects of the glucagon-like polypeptide-1 analogue (Val8)GLP-1 on learning, progenitor cell proliferation and neurogenesis in the C57B/16 mouse brain | Q48418316 |
| Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease | Q48614100 | ||
| Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis. | Q51021916 | ||
| Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes. | Q51353782 | ||
| Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice. | Q51387538 | ||
| A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice. | Q51754121 | ||
| Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with typ | Q53261592 | ||
| Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. | Q53886146 | ||
| Glycated cholecystokinin-8 has an enhanced satiating activity and is protected against enzymatic degradation. | Q54123643 | ||
| Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials. | Q54687755 | ||
| Chronic Reduction of GIP Secretion Alleviates Obesity and Insulin Resistance Under High-Fat Diet Conditions | Q57591294 | ||
| Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs | Q62764221 | ||
| Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. | Q64998688 | ||
| Effects of Ingestion of Triglyceride or Galactose on Secretion of Gastric Inhibitory Polypeptide and on Responses to Intravenous Glucose in Normal and Diabetic Subjects | Q67317479 | ||
| Gastric inhibitory polypeptide activates MAP kinase through the wortmannin-sensitive and -insensitive pathways | Q73442906 | ||
| Oxyntomodulin suppresses appetite and reduces food intake in humans | Q79161514 | ||
| Lack of tolerance development with long-term administration of PEGylated cholecystokinin | Q82974141 | ||
| Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus | Q85358566 | ||
| (pGlu-Gln)-CCK-8[mPEG]: a novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetes | Q86590037 | ||
| Liraglutide, the glucagon-like peptide-1 receptor agonist, has anabolic bone effects in diabetic Goto-Kakizaki rats | Q86891278 | ||
| A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat-Fed Mice | Q87132078 | ||
| Metabolic effects of activation of CCK receptor signaling pathways by twice-daily administration of the enzyme-resistant CCK-8 analog, (pGlu-Gln)-CCK-8, in normal mice | Q87427418 | ||
| DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats | Q87428531 | ||
| Double incretin receptor knock-out (DIRKO) mice present with alterations of trabecular and cortical micromorphology and bone strength | Q87587380 | ||
| Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors | Q24598747 | ||
| New drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseases | Q26866194 | ||
| Unraveling oxyntomodulin, GLP1's enigmatic brother | Q27001704 | ||
| Pharmacology, physiology, and mechanisms of incretin hormone action | Q27021545 | ||
| Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors | Q28145693 | ||
| Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants | Q28238585 | ||
| Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain | Q28256443 | ||
| Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety | Q28287902 | ||
| GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1 | Q28289025 | ||
| Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor | Q28295907 | ||
| Effects of glucose-dependent insulinotropic peptide on behavior | Q28504780 | ||
| Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid | Q28565656 | ||
| Cardiac function in mice lacking the glucagon-like peptide-1 receptor | Q28586718 | ||
| Cholecystokinin receptors | Q28608935 | ||
| Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data | Q31144148 | ||
| Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion | Q33529942 | ||
| Incretin receptor null mice reveal key role of GLP-1 but not GIP in pancreatic beta cell adaptation to pregnancy | Q33753169 | ||
| Role of endogenous GLP-1 and GIP in beta cell compensatory responses to insulin resistance and cellular stress | Q33812543 | ||
| Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes | Q33873009 | ||
| Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism | Q33924273 | ||
| Receptors and effects of gut hormones in three osteoblastic cell lines | Q33975451 | ||
| The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose | Q34014522 | ||
| Cholecystokinin | Q34096294 | ||
| Cholecystokinin is up-regulated in obese mouse islets and expands beta-cell mass by increasing beta-cell survival | Q34132510 | ||
| Glucose-dependent insulinotropic polypeptide receptor deficiency leads to modifications of trabecular bone volume and quality in mice | Q34316123 | ||
| Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality. | Q34357351 | ||
| A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. | Q34421364 | ||
| Proglucagon-derived peptides: mechanisms of action and therapeutic potential | Q34452524 | ||
| The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. | Q34585388 | ||
| Gastrointestinal regulation of food intake | Q35251043 | ||
| Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential? | Q35579570 | ||
| Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans | Q42464329 | ||
| Deciphering metabolic messages from the gut drives therapeutic innovation: the 2014 Banting Lecture | Q42471846 | ||
| Beneficial effects of a N-terminally modified GIP agonist on tissue-level bone material properties | Q42805863 | ||
| Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study | Q43255700 | ||
| Effects of chronic exposure of clonal β-cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP-1. | Q43651347 | ||
| Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes | Q43726354 | ||
| Effects of cholecystokinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide (GIP) on basal and meal-stimulated pancreatic hormone secretion in man | Q43947295 | ||
| The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice | Q44704405 | ||
| Induction of beta-cell rest by a Kir6.2/SUR1-selective K(ATP)-channel opener preserves beta-cell insulin stores and insulin secretion in human islets cultured at high (11 mM) glucose | Q44757149 | ||
| Sulfonylurea induced beta-cell apoptosis in cultured human islets | Q45105959 | ||
| Xenin-25[Lys13PAL]: a novel long-acting acylated analogue of xenin-25 with promising antidiabetic potential | Q45378064 | ||
| Beneficial effects of (pGlu-Gln)-CCK-8 on energy intake and metabolism in high fat fed mice are associated with alterations of hypothalamic gene expression | Q45796873 | ||
| Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture. | Q45918551 | ||
| Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist | Q46131933 | ||
| Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice | Q46203073 | ||
| KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes | Q46218694 | ||
| Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes | Q46226028 | ||
| Dorothy Hodgkin Lecture 2008. Gastric inhibitory polypeptide (GIP) revisited: a new therapeutic target for obesity-diabetes? | Q46567054 | ||
| Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial | Q46620662 | ||
| Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study | Q46850405 | ||
| Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance | Q46942344 | ||
| The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose | Q46972113 | ||
| Glucose-dependent insulinotropic peptide: differential effects on hepatic artery vs. portal vein endothelial cells | Q47280771 | ||
| A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents | Q48246762 | ||
| Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease | Q48270990 | ||
| Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline | Q48379621 | ||
| Restoration of cerebral and systemic microvascular architecture in APP/PS1 transgenic mice following treatment with Liraglutide™. | Q48392292 | ||
| Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL/KsJ db/db mice. | Q35655010 | ||
| Physiology of incretins in health and disease | Q35760279 | ||
| Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus | Q35824086 | ||
| Glucagon like peptide-1 receptor expression in the human thyroid gland | Q36141532 | ||
| Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes | Q36520758 | ||
| Gut hormones and appetite control | Q36820186 | ||
| Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature | Q36872178 | ||
| A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe? | Q36942123 | ||
| Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. | Q37521930 | ||
| The role of gut hormones in the regulation of body weight and energy homeostasis | Q37535112 | ||
| Do GLP-1-based therapies increase cancer risk? | Q37577143 | ||
| Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease? | Q37779101 | ||
| The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review | Q37864256 | ||
| The gut endocrine system as a coordinator of postprandial nutrient homoeostasis | Q38036016 | ||
| A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo. | Q38041660 | ||
| Enteroendocrine hormone mimetics for the treatment of obesity and diabetes | Q38142518 | ||
| The role of incretin-based therapies in prediabetes: a review | Q38199251 | ||
| Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy. | Q38199984 | ||
| Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. | Q38201586 | ||
| Gastrointestinal hormones and their targets | Q38226510 | ||
| Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials | Q38235219 | ||
| Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide. | Q38299362 | ||
| Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents | Q38304318 | ||
| Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice. | Q38320627 | ||
| Degradation, insulin secretion, glucose-lowering and GIP additive actions of a palmitate-derivatised analogue of xenin-25. | Q38325630 | ||
| Studying pancreatic risks caused by incretin-based therapies: is it a game? It's not a game! | Q38601929 | ||
| A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties | Q39177528 | ||
| Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice | Q39198588 | ||
| Processing of proglucagon to GLP-1 in pancreatic α-cells: is this a paracrine mechanism enabling GLP-1 to act on β-cells? | Q39499843 | ||
| (D-Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions | Q39663862 | ||
| Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. | Q39732229 | ||
| Glucose intolerance and reduced proliferation of pancreatic beta-cells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function | Q40132400 | ||
| Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects* | Q40329405 | ||
| Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and dow | Q40437409 | ||
| Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. | Q40637074 | ||
| Functional GIP receptors play a major role in islet compensatory response to high fat feeding in mice | Q41420211 | ||
| Mechanism of metabolic advantages after bariatric surgery: it's all gastrointestinal factors versus it's all food restriction. | Q41945986 | ||
| Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice | Q41982493 | ||
| GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice | Q41984767 | ||
| Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake | Q42210115 | ||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1285-95 | |
| P577 | publication date | 2015-11-10 | |
| P1433 | published in | World journal of diabetes | Q27723539 |
| P1476 | title | New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders | |
| P478 | volume | 6 |
| Q38610892 | Anti-diabetic actions of esculentin-2CHa(1-30) and its stable analogues in a diet-induced model of obesity-diabetes. |
| Q51282489 | Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice. |
| Q39042377 | Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease |
| Q50171023 | Intestinal Incretins and the Regulation of Bone Physiology |
| Q58696244 | Long-term treatment with acylated analogues of apelin-13 amide ameliorates diabetes and improves lipid profile of high-fat fed mice |
| Q39205071 | Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes |
| Q38767234 | The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease |
| Q88595062 | [Nicorandil improves cognitive dysfunction in mice with streptozotocin-induced diabetes] |
Search more.